|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Morgan RJ Jr, Alvarez RD, Armstrong DK,
Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray
HJ, Hakam A, et al: Ovarian cancer, version 2.2013. J Natl Compr
Canc Netw. 11:1199–1209. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Di Francia R, De Lucia L, Di Paolo M, Di
Martino S, Del Pup L, De Monaco A, Lleshi A and Berretta M:
Rational selection of predictive pharmacogenomics test for the
Fluoropyrimidine/Oxaliplatin based therapy. Eur Rev Med Pharmacol
Sci. 19:4443–4454. 2015.PubMed/NCBI
|
|
5
|
Ding L, Wang XQ, Zhang J, Mu ZL, Zhou XX
and Liu PS: Underlying mechanism of 2-methoxyestradiol-induced
apoptosis and growth arrest in SKOV3 human ovarian cancer cells.
Eur Rev Med Pharmacol Sci. 19:2084–2090. 2015.PubMed/NCBI
|
|
6
|
Sestito R, Cianfrocca R, Rosanò L, Tocci
P, Semprucci E, Di Castro V, Caprara V, Ferrandina G, Sacconi A,
Blandino G and Bagnato A: miR-30a inhibits endothelin A receptor
and chemoresistance in ovarian carcinoma. Oncotarget. 7:4009–4023.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu X, Shen H, Yin X, Long L, Xie C, Liu
Y, Hui L, Lin X, Fang Y, Cao Y, et al: miR-186 regulation of Twist1
and ovarian cancer sensitivity to cisplatin. Oncogene. 35:323–332.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang J, Yin XJ, Xu CJ, Ning YX, Chen M,
Zhang H, Chen SF and Yao LQ: The histone deacetylase SIRT6 inhibits
ovarian cancer cell proliferation via down-regulation of Notch 3
expression. Eur Rev Med Pharmacol Sci. 19:818–824. 2015.PubMed/NCBI
|
|
9
|
Moisan F, Francisco EB, Brozovic A, Duran
GE, Wang YC, Chaturvedi S, Seetharam S, Snyder LA, Doshi P and
Sikic BI: Enhancement of paclitaxel and carboplatin therapies by
CCL2 blockade in ovarian cancers. Mol Oncol. 8:1231–1239. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu S, Sun J, Cai B, Xi X, Yang L, Zhang
Z, Feng Y and Sun Y: NANOG regulates epithelial-mesenchymal
transition and chemoresistance through activation of the STAT3
pathway in epithelial ovarian cancer. Tumour Biol. 37:9671–9680.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kouzarides T: Chromatin modifications and
their function. Cell. 128:693–705. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Christensen J, Agger K, Cloos PA, Pasini
D, Rose S, Sennels L, Rappsilber J, Hansen KH, Salcini AE and Helin
K: RBP2 belongs to a family of demethylases, specific for tri-and
dimethylated lysine 4 on histone 3. Cell. 128:1063–1076. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lopez-Bigas N, Kisiel TA, Dewaal DC,
Holmes KB, Volkert TL, Gupta S, Love J, Murray HL, Young RA and
Benevolenskaya EV: Genome-wide analysis of the H3K4 histone
demethylase RBP2 reveals a transcriptional program controlling
differentiation. Mol Cell. 31:520–530. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pasini D, Hansen KH, Christensen J, Agger
K, Cloos PA and Helin K: Coordinated regulation of transcriptional
repression by the RBP2 H3K4 demethylase and polycomb-repressive
complex 2. Genes Dev. 22:1345–1355. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Defeo-Jones D, Huang PS, Jones RE, Haskell
KM, Vuocolo GA, Hanobik MG, Huber HE and Oliff A: Cloning of cDNAs
for cellular proteins that bind to the retinoblastoma gene product.
Nature. 352:251–254. 1991. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gildea JJ, Lopez R and Shearn A: A screen
for new trithorax group genes identified little imaginal discs, the
Drosophila melanogaster homologue of human retinoblastoma binding
protein 2. Genetics. 156:645–663. 2000.PubMed/NCBI
|
|
17
|
Zeng J, Ge Z, Wang L, Li Q, Wang N,
Björkholm M, Jia J and Xu D: The histone demethylase RBP2 Is
overexpressed in gastric cancer and its inhibition triggers
senescence of cancer cells. Gastroenterology. 138:981–992. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin W, Cao J, Liu J, Beshiri ML, Fujiwara
Y, Francis J, Cherniack AD, Geisen C, Blair LP, Zou MR, et al: Loss
of the retinoblastoma binding protein 2 (RBP2) histone demethylase
suppresses tumorigenesis in mice lacking Rb1 or Men1. Proc Natl
Acad Sci USA. 108:13379–13386. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hou J, Wu J, Dombkowski A, Zhang K,
Holowatyj A, Boerner JL and Yang ZQ: Genomic amplification and a
role in drug- resistance for the KDM5A histone demethylase in
breast cancer. Am J Transl Res. 4:247–256. 2012.PubMed/NCBI
|
|
20
|
Liu G, Bollig-Fischer A, Kreike B, van de
Vijver MJ, Abrams J, Ethier SP and Yang ZQ: Genomic amplification
and oncogenic properties of the GASC1 histone demethylase gene in
breast cancer. Oncogene. 28:4491–4500. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sharma SV, Lee DY, Li B, Quinlan MP,
Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach
MA, et al: A chromatin-mediated reversible drug-tolerant state in
cancer cell subpopulations. Cell. 141:69–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Banelli B, Carra E, Barbieri F, Würth R,
Parodi F, Pattarozzi A, Carosio R, Forlani A, Allemanni G, Marubbi
D, et al: The histone demethylase KDM5A is a key factor for the
resistance to temozolomide in glioblastoma. Cell Cycle.
14:3418–3429. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cao H, Xu E, Liu H, Wan L and Lai M:
Epithelial-mesenchymal transition in colorectal cancer metastasis:
A system review. Pathol Res Pract. 211:557–569. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Reck M, Heigener DF, Mok T, Soria JC and
Rabe KF: Management of non-small-cell lung cancer: Recent
developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao F, Siu MK, Jiang L, Tam KF, Ngan HY,
Le XF, Wong OG, Wong ES, Gomes AR, Bella L, et al: Overexpression
of forkhead box protein M1 (FOXM1) in ovarian cancer correlates
with poor patient survival and contributes to paclitaxel
resistance. PLoS One. 9:e1134782014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Grant S: Targeting histone demethylases in
cancer therapy. Clin Cancer Res. 15:7111–7113. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Natoli G, Testa G and De Santa F: The
future therapeutic potential of histone demethylases: A critical
analysis. Curr Opin Drug Discov Devel. 12:607–615. 2009.PubMed/NCBI
|
|
29
|
Agarwal R and Kaye SB: Ovarian cancer:
Strategies for overcoming resistance to chemotherapy. Nat Rev
Cancer. 3:502–516. 2003. View
Article : Google Scholar : PubMed/NCBI
|
